Breaking News

Thermo Fisher Streamlines Pre-Clinical Biologic Drug Development

Enhanced platform technology and the addition of a robust, high-quality CHO K-1 cell line decrease lead time to Investigational New Drug (IND).

Author Image

By: Charlie Sternberg

Associate Editor

Thermo Fisher Scientific is employing an enhanced platform technology and a new CHO K-1 cell line that can reduce timelines to Investigational New Drug (IND) filing from 13 to nine months, helping biotech and pharmaceutical companies overcome logistical complexities within pre-clinical biologic drug development. The new CHO K-1 cell line is able to deliver up to 8g/L, providing higher protein expression levels and increased stability, allowing customers to achieve greater productivity from pr...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters